Moderna said on Thursday it secured a five-year loan of $1.5 billion from Ares Management , as it targets up to 10% revenue ...

The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

With much of Moderna’s rise in this decade tied to its COVID-19 vaccine, the company has struggled in recent years to match ...

Get the latest stock market update and key takeaways in healthcare, including Pfizer, Amgen, Novo Nordisk results, and obesity drug bidding wars.

Moderna will invest $140 million in expanding its U.S. manufacturing capacity and onshoring its drug manufacturing to its existing facility in Norwood, Mass. The company said it will now operate full ...

Moderna said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U.S., marking a ...

The deals keeps coming. Merck this morning said it will acquire Cidara Therapeutics, the maker of an experimental flu therapy ...

Pfizer saw U.S. Comirnaty sales drop to $870 million in the recently completed third quarter from $1.16 billion in the same time frame last year. That came after vaccine sales rose the first two ...

A new mRNA-based flu vaccine from Pfizer has shown greater effectiveness than the standard flu shot in a large Phase 3 trial, according to results published in the New England Journal of Medicine. The ...

Moderna on Thursday also trimmed its adjusted operating expenses outlook for 2025 by $700 million to a range of $5.2 billion to $5.4 billion. Copyright 2025 Thomson Reuters.